High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia

L. M. El-Helw, M. J. Seckl, R. Haynes, L. S. Evans, P. C. Lorigan, J. Long, E. J. Kanfer, E. S. Newlands, B. W. Hancock

    Research output: Contribution to journalArticlepeer-review

    Abstract

    We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for refractory gestational trophoblastic neoplasia (GTN) in the largest series so far reported. In all, 11 patients have been treated at three Trophoblast Centres between 1993 and 2004. The conditioning regimens comprised either Carbop-EC-T (carboplatin, etoposide, cyclophosphamide, paclitaxel and prednisolone) or CEM (carboplatin, etoposide and melphalan) or ICE (ifosfamide, carboplatin, etoposide). Two patients had complete human chorionic gonadotrophin responses, one for 4 and the other for 12 months. Three patients had partial tumour marker responses for 1-2 months. High-dose chemotherapy and HSCS for GTN is still unproven. Further studies are needed, perhaps in high-risk patients who fail their first salvage treatment. © 2005 Cancer Research.
    Original languageEnglish
    Pages (from-to)620-621
    Number of pages1
    JournalBritish Journal of Cancer
    Volume93
    Issue number6
    DOIs
    Publication statusPublished - 19 Sept 2005

    Keywords

    • Gestational trophoblastic neoplasia
    • High-dose chemotherapy

    Fingerprint

    Dive into the research topics of 'High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia'. Together they form a unique fingerprint.

    Cite this